Cognition Therapeutics, Inc. (NasdaqCM: CGTX)
Health Care · Pharmaceuticals · US
$1.05
+5.43% today · -68.7% 1Y
Cognition Therapeutics, Inc. (NasdaqCM: CGTX) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $94.70M and employs 14 people.
Over the last twelve months the share price has lost 68.7%, trading between 0.55 and 3.83.
Tweenvest scores Cognition Therapeutics, Inc. across four factors: quality 26/100. Its strongest factor is quality.
CGTX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $94.70M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.19
- Dividend yield
- —
- Beta (5Y)
- 1.78
- 52-week high
- $3.83
- 52-week low
- $0.55
- Avg volume (3M)
- —
- Shares outstanding
- 95.09M
- Employees
- 14
- Next earnings
- —
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
- ISIN
- US19243B1026
- Founded
- 2007
- Listed since
- Oct 8, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.